Basem M William1, Wei An2,3, Dan Feng3, Scott Nadeau2,3, Bhopal C Mohapatra3,4, Matthew A Storck3, Vimla Band2,3,5, Hamid Band2,3,4,5. 1. a Division of Hematology and Oncology, Department of Medicine , University of Nebraska Medical Center , Omaha , USA. 2. b Department of Genetics, Cell Biology and Anatomy , University of Nebraska Medical Center , Omaha , USA. 3. c Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha , USA. 4. d Department of Biochemistry and Molecular Biology , University of Nebraska Medical Center , Omaha , USA. 5. e Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha , USA.
Abstract
OBJECTIVES: Mutations in Cbl or Cbl-b gene occur in 10% of myeloproliferative disorder (MPD) patients and are associated with poor prognosis. Hematopoietic Cbl/Cbl-b double knockout (DKO) leads to a disease in mice phenotypically similar to human MPDs. The aim of this study was to evaluate the anti-MPD activity of a clinically safe drug, Fasudil, identified in an in vitro kinase inhibitor as an inhibitor of proliferation of DKO mouse hematopoietic stem/progenitor cells (HSPCs). METHODS: Fasudil exhibited relatively selective anti-proliferative activity against Cbl/Cbl-b DKO vs. control murine bone marrow HSPCs. We established a mouse model with uniform time of MPD onset by transplanting Cbl/Cbl-b DKO HSPCs into busulfan-conditioned NOD/SCID/gamma chain-deficient mice. Four weeks post-transplant, mice were treated with 100 mg/kg fasudil (13 mice) or water (control, 8 mice) daily by oral gavage, followed by blood cell count every 2 weeks. RESULTS: By 2 weeks of treatment, total white cell and monocyte counts were significantly lower in mice treated with fasudil. We observed a trend towards improved survival in fasudil-treated mice that did not reach statistical significance. Notably, prolonged survival beyond 27 weeks was observed in two fasudil-treated mice, nearly twice the 16-week average life-span in the Cbl/Cbl-b DKO MPD model. CONCLUSIONS: Our results suggest a therapeutic potential for fasudil, a clinically safe drug with promising results in vascular diseases, in the treatment of MPDs or other mutant Cbl-driven myeloid disorders.
OBJECTIVES: Mutations in Cbl or Cbl-b gene occur in 10% of myeloproliferative disorder (MPD) patients and are associated with poor prognosis. Hematopoietic Cbl/Cbl-b double knockout (DKO) leads to a disease in mice phenotypically similar to humanMPDs. The aim of this study was to evaluate the anti-MPD activity of a clinically safe drug, Fasudil, identified in an in vitro kinase inhibitor as an inhibitor of proliferation of DKO mouse hematopoietic stem/progenitor cells (HSPCs). METHODS:Fasudil exhibited relatively selective anti-proliferative activity against Cbl/Cbl-b DKO vs. control murine bone marrow HSPCs. We established a mouse model with uniform time of MPD onset by transplanting Cbl/Cbl-b DKO HSPCs into busulfan-conditioned NOD/SCID/gamma chain-deficient mice. Four weeks post-transplant, mice were treated with 100 mg/kg fasudil (13 mice) or water (control, 8 mice) daily by oral gavage, followed by blood cell count every 2 weeks. RESULTS: By 2 weeks of treatment, total white cell and monocyte counts were significantly lower in mice treated with fasudil. We observed a trend towards improved survival in fasudil-treated mice that did not reach statistical significance. Notably, prolonged survival beyond 27 weeks was observed in two fasudil-treated mice, nearly twice the 16-week average life-span in the Cbl/Cbl-b DKO MPD model. CONCLUSIONS: Our results suggest a therapeutic potential for fasudil, a clinically safe drug with promising results in vascular diseases, in the treatment of MPDs or other mutant Cbl-driven myeloid disorders.
Authors: A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu Journal: Leukemia Date: 2014-01-10 Impact factor: 11.528
Authors: Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross Journal: Blood Date: 2005-05-26 Impact factor: 22.113
Authors: Raghuveer Singh Mali; Baskar Ramdas; Peilin Ma; Jianjian Shi; Veerendra Munugalavadla; Emily Sims; Lei Wei; Sasidhar Vemula; Sarah C Nabinger; Charles B Goodwin; Rebecca J Chan; Fabiola Traina; Valeria Visconte; Ramon V Tiu; Timothy A Lewis; Andrew M Stern; Qiang Wen; John D Crispino; H Scott Boswell; Reuben Kapur Journal: Cancer Cell Date: 2011-09-13 Impact factor: 31.743
Authors: Wei An; Scott A Nadeau; Bhopal C Mohapatra; Dan Feng; Neha Zutshi; Matthew D Storck; Priyanka Arya; James E Talmadge; Jane L Meza; Vimla Band; Hamid Band Journal: Oncotarget Date: 2015-04-30
Authors: Diana Saleiro; Jeremy Q Wen; Ewa M Kosciuczuk; Frank Eckerdt; Elspeth M Beauchamp; Chidera V Oku; Gavin T Blyth; Mariafausta Fischietti; Liliana Ilut; Marco Colamonici; William Palivos; Paula A Atsaves; Dean Tan; Masha Kocherginsky; Rona Singer Weinberg; Eleanor N Fish; John D Crispino; Ronald Hoffman; Leonidas C Platanias Journal: Nat Commun Date: 2022-04-01 Impact factor: 17.694